Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study.

摘要: Background Influenza may cause severe disease in immunosuppressed patients. Different vaccines have been proved to be efficacious prevent influenza tranplant recipients. Since the last five years addition of adjuvants improve immune response vaccine preparations has proposed and evaluated. In this study, two antigenically identical vaccines, but different for presence were randomised among a cohort heart transplant recipients evaluate their safety immunogenicity. Methods 58 patients, receiving an more than 6 months before, receive one shoot vaccination with Fluad (containing MF59 adjuvant) or Agrippal (no adjuvant added) enter control, not-vaccinated, group. The was evaluated separately type A B viruses IgG IgM antibodies. Patients clinically at least monthly up months. Results symptoms reported by 33% patients Fluad, 29% 63% control 4 episodes acute myocardial rejection ≥3A identified without difference between three groups. Conclusions superior efficacy containing not found data clearly confirmed that against is safe effective use substances do ameliorate clinical performance immunisation suggesting less expensive preparation could equally useful protect